A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

NCT04480710 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH - Nonalcoholic Steatohepatitis
Fibrosis, Liver
NAFLD - Nonalcoholic Fatty Liver Disease

Interventions

DRUG: CRV431 75mg
DRUG: Placebo (1 softgel)
DRUG: CRV431 225mg
DRUG: Placebo (3 softgels)

Sponsor

Hepion Pharmaceuticals, Inc.